Oral Micronized Progesterone Regulatory Status: US, EU, Canada, UK

How Oral Micronized Progesterone Works

OMP delivers bioidentical progesterone (identical to the molecule produced by the corpus luteum) in a micronized particle form suspended in oil to overcome the drug's otherwise poor oral bioavailability. Micronization reduces particle diameter to approximately 10 micrometers, increasing surface area and intestinal absorption [1].

After absorption, progesterone binds nuclear progesterone receptors (PR-A and PR-B) in target tissues. In the endometrium, receptor activation halts estrogen-driven proliferation and converts glandular epithelium to a secretory phenotype. This transformation is the pharmacologic basis for endometrial protection during menopausal estrogen therapy [2]. The drug also modulates GABA-A receptors through its neurosteroid metabolite allopregnanolone, which accounts for the sedative effect that led regulators to recommend bedtime dosing.

Peak serum progesterone concentrations occur 1 to 3 hours post-dose (Tmax varies with fed/fasted state). The elimination half-life ranges from 16 to 18 hours after oral administration with food, though considerable inter-patient variability exists due to first-pass hepatic metabolism via 5-alpha reductase and CYP enzymes [3].

United States: FDA Approval and Labeled Indications

The FDA approved Prometrium (Solvay Pharmaceuticals, now AbbVie) in 1998 under NDA 19-781 for two indications: secondary amenorrhea and prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women receiving conjugated estrogens [4]. The approval relied partly on efficacy data from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, which enrolled 875 women and demonstrated that OMP 200 mg/day for 12 days per cycle provided endometrial protection comparable to medroxyprogesterone acetate 10 mg/day while preserving estrogen's favorable effects on HDL cholesterol [5].

The labeled dose for endometrial protection is 200 mg orally at bedtime for 12 consecutive days per 28-day cycle when used sequentially, or 100 mg nightly when used continuously. The secondary amenorrhea indication calls for 400 mg at bedtime for 10 days.

Generic OMP capsules became available in the US after 2018. The FDA's Orange Book lists multiple ANDA holders. All approved US formulations use peanut oil as the suspension vehicle, creating a contraindication for patients with peanut allergy. This excipient choice has been a recurring point of clinical concern, and the FDA labeling carries a specific peanut allergy warning [4].

Off-label use extends to luteal phase support in assisted reproduction and to cyclic progesterone withdrawal in premenopausal anovulatory bleeding. The American College of Obstetricians and Gynecologists (ACOG) recognizes OMP as a preferred progestogen for endometrial protection in menopausal HRT, citing its more favorable cardiovascular and breast safety profile compared with synthetic progestins [6].

European Union: National Authorizations and the Utrogestan Brand

OMP has been marketed in EU member states since the early 1980s, predating centralized EMA marketing authorization procedures. The reference brand in most EU countries is Utrogestan (Besins Healthcare), authorized through national mutual recognition and decentralized procedures rather than a single centralized EMA authorization [7].

Labeled indications across EU member states typically include:

• Luteal insufficiency (including luteal phase support in IVF cycles)
• Endometrial protection during estrogen replacement therapy
• Premenstrual syndrome
• Irregular cycles secondary to dysovulation or anovulation
• Threatened or habitual abortion (in some member states)

This indication set is broader than the US label. The inclusion of luteal phase support for early pregnancy and IVF reflects European regulatory traditions that recognize progesterone's physiologic role in implantation.

Dose forms approved in Europe include 100 mg and 200 mg capsules intended for both oral and vaginal administration. The dual-route authorization is a notable distinction from the US, where Prometrium is approved only for oral use. European formulations typically use sunflower oil rather than peanut oil, eliminating the peanut allergy concern [7].

The 2024 revised International Menopause Society (IMS) position statement and the European Menopause and Andropause Society (EMAS) guidelines both recommend micronized progesterone as a first-line progestogen for endometrial protection in HRT, based on evidence suggesting lower venous thromboembolism (VTE) risk compared with synthetic progestins. Data from the E3N French cohort (N=80,377) showed no significant increase in breast cancer risk with estrogen plus micronized progesterone over a mean 8.1-year follow-up, in contrast to estrogen plus synthetic progestins [8].

Canada: Health Canada Authorization

Health Canada approved Prometrium (then under Solvay, now Organon Canada) with Drug Identification Number (DIN) 02243830. The Canadian product monograph lists indications for secondary amenorrhea, dysfunctional uterine bleeding, and prevention of estrogen-induced endometrial hyperplasia in postmenopausal women [9].

The Canadian formulation mirrors the US product in using peanut oil. Available strengths are 100 mg capsules. The Society of Obstetricians and Gynaecologists of Canada (SOGC) 2021 guidelines on menopause management recommend micronized progesterone as a preferred progestogen option, citing evidence from the PEPI trial and observational data suggesting a more favorable breast and cardiovascular risk profile compared with medroxyprogesterone acetate [10].

Canadian prescribers commonly use OMP at 200 mg nightly for 12 to 14 days per month (sequential) or 100 mg nightly (continuous). Generic availability has expanded access, with several manufacturers holding approvals. Provincial formulary coverage varies. Ontario's Ontario Drug Benefit program and British Columbia's PharmaCare include OMP on their formularies for menopausal HRT indications, though some provinces require Limited Use codes [9].

United Kingdom: MHRA Licensing Post-Brexit

In the UK, Utrogestan (Besins Healthcare UK) holds a Marketing Authorization from the Medicines and Healthcare products Regulatory Agency (MHRA). Following Brexit, the UK operates its own regulatory pathway independent of EU decisions, though existing Marketing Authorizations granted before January 31, 2021 were grandfathered into UK law [11].

The MHRA-licensed indications for Utrogestan include:

• HRT: opposition of the endometrial effects of estrogen in women with an intact uterus
• Assisted reproduction: luteal phase support

The UK's National Institute for Health and Care Excellence (NICE) guideline NG23 on menopause (updated 2024) recommends body-identical (micronized) progesterone as part of HRT regimens, specifically noting lower rates of VTE and breast cancer risk compared with older synthetic progestogens [12]. This NICE endorsement has increased UK prescribing substantially. NHS prescription data show a greater than 300% increase in Utrogestan dispensing between 2017 and 2023.

The British Menopause Society (BMS) position statement further supports micronized progesterone as a preferred option. Dr. Haitham Hamoda, Chair of the BMS, stated in the Society's 2020 tools for clinicians document: "Micronised progesterone is associated with fewer adverse metabolic effects and may be associated with a lower risk of breast cancer compared with synthetic progestogens" [13].

UK formulations use sunflower oil. The 100 mg capsule is licensed for both oral and vaginal administration, providing prescribers flexibility for patients who experience unacceptable somnolence with oral dosing.

Comparative Regulatory Summary

The four markets share a core indication (endometrial protection during HRT) but diverge on several points. The EU and UK authorize vaginal administration on-label; the US does not. The EU includes early pregnancy indications; the US and Canada do not. All four require a prescription.

A practical difference: the peanut oil vehicle in US and Canadian formulations creates a safety concern absent in EU/UK sunflower oil formulations. Clinicians in North America prescribing to peanut-allergic patients must either use compounded preparations or vaginal progesterone products (Endometrin, Crinone) as alternatives.

Regarding generic competition, the US market opened to ANDA-approved generics after patent expiry. The EU has long had multiple manufacturers given the decentralized authorization history. In Canada, generic entry followed a similar trajectory to the US. The UK has seen supply constraints periodically, prompting the Department of Health and Social Care to issue Serious Shortage Protocols for Utrogestan as recently as 2022 [14].

Safety Signal Differences Across Labels

All four regulatory labels carry warnings about VTE, though the magnitude of attributed risk differs by jurisdiction. The FDA label includes a boxed warning inherited from the Women's Health Initiative (WHI) class labeling for all estrogen-progestin products, despite the WHI using medroxyprogesterone acetate rather than micronized progesterone [15]. This class-effect warning has been criticized by menopause specialists who argue it overstates risk for OMP specifically.

The MHRA and EMA labels contain VTE warnings without boxed-warning formatting, and both cite the ESTHER study (Canonico et al., 2007) which found no significant VTE increase with transdermal estrogen plus micronized progesterone (OR 0.9 to 95% CI 0.4 to 2.1) compared with non-users [16]. The NICE guideline explicitly states that body-identical progesterone combined with transdermal estradiol is associated with little or no increase in VTE risk.

Breast cancer risk language also diverges. The FDA label applies WHI class warnings. European and UK labels reference the E3N data and the Collaborative Group on Hormonal Factors in Breast Cancer 2019 meta-analysis, which found lower relative risk with micronized progesterone than with synthetic progestins, though acknowledged the evidence base is smaller [8].

Current Regulatory Developments

Several regulatory developments are in progress across markets. The FDA accepted a Citizen Petition in 2023 requesting removal of the WHI class-label boxed warning for progesterone-only products, arguing the data do not support a class effect. No final determination has been published as of May 2026. In the EU, a PRAC signal assessment reviewed post-marketing reports of depressive symptoms with OMP, concluding that the product information should include depression as a possible adverse reaction. The UK MHRA has aligned with this recommendation [17].

Australia's Therapeutic Goods Administration (TGA) approved Prometrium in 2022, expanding the global regulatory footprint. While outside the four markets in scope, this approval provides additional post-marketing safety data that feeds back into pharmacovigilance systems of all regulators.